A Phase I Open Label Study of E7974 Administered on Day 1 of a 21-Day Cycle In Patients With Advanced Solid Tumors.
Latest Information Update: 12 Sep 2009
At a glance
- Drugs E 7974 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 11 Aug 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 11 Aug 2009 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
- 12 Dec 2008 Status changed from recruiting to active, no longer recruiting, as reported in ClinicalTrials.gov record.